在肺癌中,新辅助剂尼沃卢马布加化疗的整体存活率
Patrick M Forde1, Jonathan D Spicer2, Mariano Provencio3
1Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin.
The New England journal of medicine
|June 2, 2025
概括
新辅助药尼沃卢马布加化疗显著改善了可切除非小细胞肺癌 (NSCLC) 的整体存活率. 与单独的化疗相比,这种联合治疗显示出5年生存益处.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胸部外科手术 胸部外科手术
背景情况:
- 新辅助药尼沃卢马布加化疗在改善可切除非小细胞肺癌 (NSCLC) 的病理完整反应和无事件生存率方面表现有希望.
- 需要更多关于整体存活时间 (OS) 的数据来充分评估治疗的疗效.
研究的目的:
- 报告计划的整体生存期 (OS) 分析,该分析来自一项研究新辅助药尼沃卢马布加上可切除NSCLC的化疗的第三期试验.
- 为了比较接受新辅助药尼沃卢马布加化疗的患者和仅接受化疗的患者之间的长期生存结果.
主要方法:
- 一项开放的第三阶段试验随机选择了358名可切除NSCLC (IB-IIIA阶段) 的患者,接受三轮nivolumab加化学疗法或单独化学疗法,然后进行手术.
- 主要终点是无事件生存率和病理完整反应,而总生存率是本分析的关键次要终点.
主要成果:
- 与单独化疗相比,新辅助药尼沃卢马布加化疗显著改善了整体生存率 (死亡风险比,0.72;P=0.048).
- 五年整体存活率为65.4%的尼沃卢马布加化疗,与单独使用化疗的55.0%相比.
- 探索性分析显示,在尼沃卢马布手臂的患者中,在获得病理完整反应 (95.3%) 或手术前循环瘤DNA (ctDNA) 清除 (75.0%) 的患者中,生存率更高.
结论:
- 新辅助药尼沃卢马布加化疗的三次循环为切除性NSCLC患者的整体存活率提供了显著的改善.
- 观察到的生存益处在各个子组中是一致的,没有发现新的安全问题.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.7K
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.7K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
